Integrating new technology into busy ophthalmic ASC

Results of this study (presented at the 2016 meeting of the American Society of Cataract and Refractive Surgery) showed that use of the phenylephrine and ketorolac injection 1%/0.3% was associated with a four-fold reduction in complications, shorter case length, and less use of pupil expansion devices-all of which resulted in significantly improved patient outcomes, reduced surgical complications, and cost savings. ADMINISTRATIVE SUPPORT The last step is providing administrative support to ensure that appropriate reimbursement is received for utilization of new technologies. Since the ASC has financial exposure for all charges related to the surgery, the center confirms patient insurance coverage to the procedure. [...]the use of the phenylephrine and ketorolac injection 1%/0.3% has increased steadily across affiliated practices and surgeons.